Sales and Marketing

Showing 15 posts of 11527 posts found.

FTC files complaint against Endo for blocking generics of its pain drugs

April 1, 2016 Business Services, Manufacturing and Production, Medical Communications, Sales and Marketing Endo International, FTC, legal, regulation

The US Federal Trade Commission (FTC) has filed a complaint against Endo International (Nasdaq: ENDP) alleging the company used illegal …

Whistleblower accuses Novartis of paying bribes in Turkey to push sales

April 1, 2016 Business Services, Medical Communications, Sales and Marketing Financial, Novartis, legal, reuters

An anonymous whistleblower has accused Swiss drugmaker Novartis (SIX: NOVN) of paying bribes in Turkey through a consulting firm to …

Janssen to stop fulranumab development in osteoarthritis pain

April 1, 2016 Medical Communications, Research and Development, Sales and Marketing Amgen, Janssen

Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain. The J&J company says the decision is …

Samsung Bioepis’ Remicade biosimilar set for CHMP verdict

March 31, 2016 Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab

Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …

Shire hikes CEO pay to £15 million

March 31, 2016 Business Services, Sales and Marketing

UK drug major Shire (LSE: SHP) has raised the compensation for the chief executive Flemming Ornskov to £15 million for …

Jazz Pharmaceuticals receives FDA approval for rare veno-occlusive disease treatment

March 31, 2016 Research and Development, Sales and Marketing FDA, jazz pharmaceuticals

Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for Defitelio …

Janssen-Cilag’s HIV treatment gets NHS backing

March 31, 2016 Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial

Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV.  The company said following the …

Bio Products Laboratory gets European approval for bleeding disorder treatment

March 30, 2016 Research and Development, Sales and Marketing Bio Products Laboratory, Coagadex, human coagulation factor X

UK-based Bio Products Laboratory has received marketing authorisation from the European Medicines Agency for Coagadex – a drug which treats …

Biogen appoints Michel Vounatsos executive vice president, chief commercial officer

March 30, 2016 Research and Development, Sales and Marketing

Biogen has appointed Michel Vounatsos as executive vice president and chief commercial officer, from April 18, 2016. Vounatsos will oversee …

Life sciences strength will drive UK pharma sector growth

March 30, 2016 Sales and Marketing

The UK pharmaceutical market is set to grow from $28.8 billion in 2015 to approximately $43 billion by 2020, at …

US lawmakers demand price cut for Astellas, Medivation’s prostate cancer drug Xtandi

March 30, 2016 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Japan, Medivation, US FDA, Xtandi, drug price

US lawmakers have asked the National Institutes of Health and the Department of Health and Human Services to ‘use its …

Shire wins v Allergan in Lialda patent case

March 30, 2016 Research and Development, Sales and Marketing Allergan, Shire, lialda

A US district court has ruled that Shire’s patent for ulcerative colitis drug Lialda is valid through 2020, leaving Allergan …

Sun Pharma forays into Japan with $293 million product buy from Novartis

March 30, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Japan, M&A, MA, Novartis, Sun Pharma, generics

Shares of Sun Pharma (BOM: 524715), the largest Indian drug maker rose over 2% Wednesday as the company announced the …

Eisai announces agreement to set up new gastrointestinal speciality company

March 30, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality

Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …

FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug

March 30, 2016 Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis

Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …
The Gateway to Local Adoption Series

Latest content